Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Nancy Davis MD

Nancy B Davis MD

Assistant Professor of Medicine, Vanderbilt University Medical Center, Disease Group Leader, Urologic Oncology, Nashville, TN

Dr. Nancy B. Davis is Assistant Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University Medical Center in Nashville, Tennessee, and the Disease Group Leader for Urologic Oncology. Her clinical practice focuses on the treatment of relapsed and metastatic genitourinary cancers, and she has a particular interest in the clinical application of new diagnostics and therapies to improve patient outcomes while maintaining quality of life.

Dr. Davis was awarded her medical degree from The University of Texas Health Science Center at Houston. She completed a residency in internal medicine and a fellowship in hematology and oncology at the University of Chicago Medical Center. She joined the Vanderbilt faculty in 2018 after successful careers in both academic and private practice oncology.

Disclosures

Dr. Davis discloses the following support for research funding: AstraZeneca, Hoffman-LaRoche, Pfizer, Merck, Incyte, Mirati Therapeutics, Seattle Genetics/Astellas,

Calithera Biosciences, Taris BioMedical, Immunomedics, Bristol Myers Squibb.

The following supplied Travel, Accommodations, Expenses: Taris BioMedical, Calithera Biosciences, Bristol-Myers Squibb.


 

Recent Contributions to PracticeUpdate:

  1. Individualized Axitinib Dosing for Patients With Metastatic Renal Cell Carcinoma
  2. Nintedanib With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Bladder Cancer
  3. Dose-Dense MVAC Versus Gemcitabine/Cisplatin for Preoperative Treatment of Muscle-Invasive Bladder Cancer
  4. Current Challenges in Management of Bladder Cancer
  5. Maintenance Immunotherapy After Chemotherapy for Metastatic Bladder Cancer
  6. Apalutamide vs Placebo Plus ADT Among Patients With Metastatic Castrate-Sensitive Prostate Cancer
  7. Adjuvant Radiation Therapy Versus Chemotherapy After Surgery for Locally Advanced Bladder Cancer

Most Read This Week

Recently Updated